Edition:
United States

Oncopeptides AB (ONCO.ST)

ONCO.ST on Stockholm Stock Exchange

112.40SEK
22 May 2018
Change (% chg)

-0.40kr (-0.35%)
Prev Close
112.80kr
Open
113.00kr
Day's High
114.60kr
Day's Low
111.40kr
Volume
72,151
Avg. Vol
89,594
52-wk High
128.40kr
52-wk Low
43.60kr

Chart for

About

Oncopeptides AB is a Sweden-based clinical development pharmaceutical company, which is primarily engaged in the healthcare industry. The Company focuses on research and development of cancer treatment solutions. The Company's product Ygalo is a peptidase potentiated alkylator, a type of cytotoxic drug that is targeted for use... (more)

Overall

Beta: --
Market Cap(Mil.): kr5,087.94
Shares Outstanding(Mil.): 43.79
Dividend: --
Yield (%): --

Financials

  ONCO.ST Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -6.34 -- --
ROI: -39.32 -7.75 12.60
ROE: -39.42 -10.55 14.49

BRIEF-Oncopeptides Completes A Directed Share Issue

* ONCOPEPTIDES HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 314 MILLION

Mar 22 2018

BRIEF-Oncopeptides To Make A Directed Share Issue

* SAYS ‍SUBSCRIPTION PRICE AND TOTAL NUMBER OF NEW SHARES IN ISSUE WILL BE DETERMINED THROUGH AN ACCELERATED BOOKBUILD PROCEDURE, NUMBER OF NEW SHARES WILL NOT EXCEED 3,980,000 ​ Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Mar 21 2018

BRIEF-Oncopeptides Additional Patent Protection For Ygalo In Japan

* ADDITIONAL PATENT PROTECTION FOR YGALO® HAS BEEN GRANTED IN JAPAN UNTIL 2033 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 08 2018

BRIEF-Oncopeptides Q4 Net Loss Up At Sek ‍66.7​ Million

* Q4 NET LOSS SEK ‍66.7​ MILLION VERSUS LOSS SEK 51.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 22 2018

Earnings vs. Estimates